COVID19. U07.1 COVID-19, virus identified•U07.2 COVID-19, virus not identifiedoClinically-epidemiologically diagnosed COVID-19oProbable COVID-19 oSuspected COVID-19
Conditions
Interventions
Intervention 1: Intervention group: the patients with diagnosis of COVID19 with be treated by tablet Levamisole 50 mg daily for 14 days in addition to standard therapies for these patients. the sign a
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: age =or > 18 years Diagnosis of COVID19 infection was made by positive test for RtPCR on nasopharyngeal swab, Lung HRCT and the opinion of infectious diseases specialist. informed consent of patient for study the possibility of patient follow up.
Exclusion criteria
Exclusion criteria: Another cause for signs and symptoms hypersensitivity to levamizole consumption of other antibiotics on the neck. Dyspnea Pregnancy breat feeding
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Improvement of the patient which has had COVOD-19>. Timepoint: 14 days. Method of measurement: evaluation of the patient by a physician. | — |
Primary
| Measure | Time frame |
|---|---|
| Discontinuation of fever. Timepoint: Daily. Method of measurement: evaluation by a physician.;Improvement of dyspnea. Timepoint: Daily. Method of measurement: evaluation by physician.;Decreasing of cogh. Timepoint: Daily. Method of measurement: evaluation by physician.;Elevation of O2sat of the blood. Timepoint: Daily. Method of measurement: evaluation by physician.;Blood presure improvement. Timepoint: Daily. Method of measurement: evaluation by physician.;Pulse rate improvement. Timepoint: Daily. Method of measurement: evaluation by physician. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMorteza Pourahmad
Esfahan University of Medical Sciences
Outcome results
None listed